摘要
目的 探讨合理的伯尔定给药计算方法。方法 5 4例Ⅲb、Ⅳ期非小细胞肺癌患者被单盲随机分为按体表面积计算伯尔定剂量组 (体表组 )和按曲线下面积 (AUC)计算组 (AUC组 ) ,观察两组的血液学毒性、近期疗效和生存率。结果 体表组和AUC组白细胞下降发生率分别为 77.8%和37.0 % ,两组差异有统计学意义 (P <0 .0 5 ) ;血小板下降发生率分别为 18.5 %和 3.7% ,血红蛋白下降均为 4 8.2 % ,差异均无统计学意义 (P >0 .0 5 )。体表组的伯尔定平均用药剂量为 (5 35 .93± 10 6 .71)mg ,AUC组为 (398.5 2± 71.72 )mg ,差异有统计学意义 (P <0 .0 1) ;两次化疗平均间隔时间分别为 (2 2 .85±2 .80 )d和 (2 7.0 4± 5 .30 )d ,差异有统计学意义 (P <0 .0 5 )。体表组和AUC组有效率分别为 2 2 .2 %和4 8.2 % (P <0 .0 5 )。 5 4例患者均可评价近期疗效和获得随访 ,随访率 10 0 %。中位生存期均为 12个月 ,1年生存率分别为 4 0 .7%和 4 4 .4 % (P >0 .0 5 )。结论 按AUC计算伯尔定的给药剂量 ,患者依从性好 ,在提高近期疗效和降低血液学毒性反应方面明显优于按体表面积计算 ,但在提高生存率方面无显著差别。
Objective To study the reasonable dosage for paraplatin according to different dosage calculations. Methods A prospective, randomized, single blinded study on 54 patients with advanced non small cell lung cancer (NSCLC) treated with paraplatin was conducted. Patients were divided to 2 groups. In group A, paraplatin dosage was calculated according to patients' body surface, and in group B, it was calculated according to the area under the curve (AUS). Hematological toxicity, response rate and survival rate in the two groups of patients were compared. Results Neutropenia in group A and group B was seen in 77.8% and 37.0% ( P < 0.05 ), and thrombocytopenia in 18.5% and 3.7%( P >0.05) of patients, respectively. Hemoglobin decrease was seen in 48.2% of patients in both groups. The average quantity of paraplatin given in one cycle of treatment was 535.93±106.71 mg and 398.52±71.72 mg( P <0.01)respectively. The average time interval between treatment cycles was 27.04±5.30 d and 22.85±2.80 d( P <0.05).The response rate and survival rate of patients in group A and B were 22.2% versus 48.2% ( P <0.05), and 40.7% versus 44.4% ( P >0.05) respectively, but the median survival time was identical (12 months) in the two groups. Conclusion NSCLC patients given paraplatin with dosages calculated on the basis of AUC have higher response rate and less severe hematological toxicity than those given paraplatin with dosages on the basis of body surface. However, the median survival time and survival rate have no statistical differences between the two groups of patients.
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2005年第1期29-32,共4页
Chinese Journal of Oncology
关键词
治疗
非小细胞肺癌
近期疗效
患者
AUC
生存率
体表
意义
差异
结论
Paraplatin
Lung neoplasm/drug therapy
Carcinoma, non small cell lung/drug therapy
Area under the curve
